Why does combined liver and kidney transplantation confer an immunologic benefit to a kidney?

R. Shapiro,A. Zeevi

DOI: https://doi.org/10.1111/j.1399-3046.2010.01336.x

2010-06-01

Pediatric Transplantation

Abstract:In their article, ‘‘Renal allograft outcome after combined liver and kidney transplantation in children: UCLA and UNOS experience,’’ by De la Cerda et al., from UCLA, the authors confirm in pediatric kidney transplant recipients an observation that has been well described (if incompletely understood) in adult recipients. Their observations that simultaneous liver/ kidney recipients have superior renal allograft survival compared with kidney alone recipients were made both in their own single center experience at UCLA and in the larger UNOS database. The incidence of acute rejection was also determined to be lower. Thus, the presence of a simultaneous liver transplant protected the kidney. A reasonable question is why this is so. In general, we tend to think of the liver as a more tolerogenic organ than the kidney. It is also understood, at a practical level, that a newly transplanted liver can transform a pre-transplantation positive cross match into a negative cross match in as little as two h. Speculation as to the mechanism has invoked the release of soluble HLA antigens into the circulation by the transplanted liver to bind and neutralize preformed anti-HLA antibodies as well as adsorption without significant graft damage. Conventionally, in a liver/kidney recipient with a positive pretransplant cross match, the liver is implanted first, and then the cross match is repeated two or more h after reperfusion. If the cross match remains positive, it is repeated again, and most of the time will become negative in time to transplant the kidney. This abrogation of the antibody response can certainly prevent early hyperacute rejection and may have long-term protective effects. One of Paul Terasaki s recent important themes has been the negative impact of donorspecific antibodies on premature renal allograft loss, and this protective effect by the liver is consistent with his observation. However, if the antibody titer pre-transplantation is high, antibody-mediated rejection of the kidney and/or liver transplant may still occur. In reality, as attractive as this mechanism of action sounds, the demonstration of the presence of soluble HLA antigens being released by the transplanted liver has been difficult to prove conclusively. The time period immediately after liver reperfusion can be a clinically hectic time in the operating room, with considerable effort being expended on achieving hemostasis in, and optimizing resuscitation of the patient, and it is not a convenient time to be drawing serial serum blood samples to dissect out the immunology. Of course, one of the things that the liver will not do is prevent calcineurin inhibitor (CNI) injury of the transplanted kidney, so that long-term chronic renal allograft damage related to CNI toxicity is certainly possible and has occurred in our own center s experience. Other potential protective effects of the liver that are mentioned in the manuscript and summarized in recent reviews include the plasticity of liver antigen presenting cells, induction of regulatory T cells, HLA-C genotype of the donor, HLA-G expression in biliary epithelial cells, and soluble HLAG in the circulation (1–3). Of particular interest are liver dendritic cell (DC) subsets that appear to play a critical role in innate and adaptive immunity. The local liver tolerogenic environment affects DC function and maturation, contributing to the regulation of hepatic inflammatory responses and modulation of T cell immunity (1). An increased ratio of plasmacytoid to myeloid precursor DCs and elevated frequencies of regulatory T cells defined as CD4+ CD25+FoxP3+ cells by flow cytometry were Pediatr Transplantation 2010: 14: 439–44